MA71324A - Utilisation d'un anticorps anti-egfr/anti-met pour traiter le cancer gastrique ou oesophagien - Google Patents

Utilisation d'un anticorps anti-egfr/anti-met pour traiter le cancer gastrique ou oesophagien

Info

Publication number
MA71324A
MA71324A MA71324A MA71324A MA71324A MA 71324 A MA71324 A MA 71324A MA 71324 A MA71324 A MA 71324A MA 71324 A MA71324 A MA 71324A MA 71324 A MA71324 A MA 71324A
Authority
MA
Morocco
Prior art keywords
egfr
esophageal cancer
met antibody
treat gastric
gastric
Prior art date
Application number
MA71324A
Other languages
English (en)
Inventor
Roland Knoblauch
Joshua CURTIN
Meena Thayu
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of MA71324A publication Critical patent/MA71324A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
MA71324A 2022-06-30 2023-06-29 Utilisation d'un anticorps anti-egfr/anti-met pour traiter le cancer gastrique ou oesophagien MA71324A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263357218P 2022-06-30 2022-06-30
PCT/IB2023/056787 WO2024003837A1 (fr) 2022-06-30 2023-06-29 Utilisation d'un anticorps anti-egfr/anti-met pour traiter le cancer gastrique ou œsophagien
EP23744239.7A EP4547715A1 (fr) 2022-06-30 2023-06-29 Utilisation d'un anticorps anti-egfr/anti-met pour traiter le cancer gastrique ou oesophagien

Publications (1)

Publication Number Publication Date
MA71324A true MA71324A (fr) 2025-04-30

Family

ID=87419298

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71324A MA71324A (fr) 2022-06-30 2023-06-29 Utilisation d'un anticorps anti-egfr/anti-met pour traiter le cancer gastrique ou oesophagien

Country Status (9)

Country Link
US (1) US20240317866A1 (fr)
EP (1) EP4547715A1 (fr)
JP (1) JP2025522814A (fr)
KR (1) KR20250029927A (fr)
CN (1) CN119790073A (fr)
AU (1) AU2023298390A1 (fr)
CA (1) CA3260989A1 (fr)
MA (1) MA71324A (fr)
WO (1) WO2024003837A1 (fr)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
CA2577082A1 (fr) 2004-09-02 2006-03-16 Genentech, Inc. Molecules heteromultimeriques
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007110205A2 (fr) 2006-03-24 2007-10-04 Merck Patent Gmbh Domaines de proteine heterodimerique d'ingenierie
WO2007147901A1 (fr) 2006-06-22 2007-12-27 Novo Nordisk A/S Production d'anticorps bispécifiques
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
ES2831374T3 (es) 2012-11-21 2021-06-08 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
KR102089591B1 (ko) * 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
US12528869B2 (en) * 2020-08-25 2026-01-20 Janssen Biotech, Inc. Treatment of non-small cell lung cancer with EGFR mutations
AR123340A1 (es) 2020-08-26 2022-11-23 Janssen Biotech Inc FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
TW202308689A (zh) 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物

Also Published As

Publication number Publication date
EP4547715A1 (fr) 2025-05-07
AU2023298390A1 (en) 2025-02-13
WO2024003837A1 (fr) 2024-01-04
CA3260989A1 (fr) 2024-01-04
CN119790073A (zh) 2025-04-08
KR20250029927A (ko) 2025-03-05
US20240317866A1 (en) 2024-09-26
JP2025522814A (ja) 2025-07-17

Similar Documents

Publication Publication Date Title
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
MA56176A (fr) Compositions et méthodes pour l'administration sous-cutanée d'une immunothérapie anticancéreuse
RU2014108042A (ru) Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
RU2014138420A (ru) Антитела против sez6 и способы их применения
RU2014108045A (ru) Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
EA201100604A1 (ru) Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
EP3833755A4 (fr) Thérapie génique non perturbatrice pour le traitement d'un mma
MA55090A (fr) Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs
EP4221715A4 (fr) Thérapie anti-inflammatoire périvasculaire pour thrombose veineuse
EP4003332A4 (fr) Composition pharmaceutique d'inhibiteur de mdm2 et son utilisation pour prévenir et/ou traiter une maladie
EP4181671A4 (fr) Modèles humanisés de souris pour l'infection par le sars-cov-2
EP4236944A4 (fr) Composés bicycliques et leurs utilisations pour le traitement de maladies
EP3931178A4 (fr) Composés pour la prévention et le traitement d'un dysfonctionnement cognitif post-opératoire
MA55872A (fr) Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires
EP3896089A4 (fr) Utilisation d'un anticorps pd-l1 d'articulation complexe de la protéine il-15 pour le traitement de maladies tumorales
EP4087571A4 (fr) Inhibiteurs cyano-pyrimidines de l'egfr/her2
EP4340881A4 (fr) Anticorps pour le traitement d'alpha-synucléinopathies
EP3936149A4 (fr) Agent thérapeutique et prophylactique pour gliome, marqueur de malignité de tumeur cérébrale, marqueur pronostique de tumeur cérébrale, procédé de détermination de la malignité et du pronostic d'une tumeur cérébrale et anticorps inhibant la prolifération tumorale
EP4104856A4 (fr) Utilisation d'anticorps anti-pd-1 dans le traitement de tumeurs
EP3934690A4 (fr) Administration de médicament pour l'association d'une modulation épigénétique et d'un blocage de point de contrôle immunitaire
EP4320163A4 (fr) Méthodes de traitement du cancer par administration sous-cutanée d'anticorps anti-pd1
EP4153216A4 (fr) Fragment c-terminal de la toxine tétanique (hc) pour le traitement de la dépression
EP3752252A4 (fr) Modulation de variants d'épissage de slamf6 pour le traitement du cancer
EP4313053A4 (fr) Pyrazolylpyrimidines pour le traitement d'une tumeur solide maligne
HK40127099A (en) Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer